DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
This grant funds early-phase clinical trials for ALS that use biomarkers or improve clinical care, requiring community collaboration, a regulatory strategy, and a plan for advancing study results.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 24, 2026: Pre-Application (Preproposal) | August 13, 2026: Regulatory application (if required) | September 30, 2026: Full application | October 6, 2026: End of Application Verification Period
Funding Amounts: Estimated total program funding: $5.6M; up to $2.8M total costs per award; project period up to 3 years; ~2 awards expected.
Summary: Supports rapid implementation of phase 1 or small phase 2 clinical trials to advance ALS treatment or management, with a focus on biomarker-driven interventions or clinical care improvements.
Key Information: Pre-application required; full applications by invitation only; community collaboration is mandatory.
Description
This opportunity supports the rapid implementation of clinical trials aimed at having a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects must be either phase 1 or small-scale phase 2 clinical trials and must directly address one of two focus areas: (1) biomarker-driven, disease-modifying interventions, or (2) clinical care and symptom management improvements for ALS. All projects must incorporate meaningful community collaboration to ensure relevance and optimize research impact. Proposals involving therapeutic interventions must integrate mechanism-specific biomarkers into the trial design. The program is intended to accelerate the translation of promising interventions or care strategies into clinical practice for the benefit of people living with ALS, including military service members and veterans.
